Who Traded Zafgen (ZFGN) on Illegal Insider Information?

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death

Cowen reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN), and cut the price target to $20.00 (from $60.00), following FDA'a decision to place beloranib on a partial clinical hold. Late yesterday ZFGN received verbal notice from the FDA that beloranib has been placed on partial... More

Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for Beloranib

RBC Capital analyst Simos Simeonidis maintained an Outperform rating and lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $58.00) following a patient death. Simeonidi said while they expect near-term uncertainty, and obviously a very negative outcome is still possible, we see a couple of viable scenarios where none of what has transpired ends up leading to any real negative impact on ZFGN.

The analyst highlighted the following scenarios:

1) The patient death was on the placebo arm (best case scenario: drug's safety profile is "exonerated").... More

Zafgen (ZFGN) PT Cut to $48 at FBR Capital on Patient Death

FBR Capital analyst Christopher James lowered his price target on Outperform Zafgen (NASDAQ: ZFGN) to $48.00 (from $60.00) following news of a patient death in its Phase III bestPWS study of beloranib in Prader-Willi syndrome (PWS). The firm maintained an Outperform rating.

James commented, "We spoke with management following the... More

RBC Sees 33% of Zafgen (ZFGN) Death Happening in Placebo Arm; Reiterates 'Outperform' Rating

RBC Capital is positive on news from Zafgen (Nasdaq: ZFGN) following news of a death with the company's Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome.

Analyst Simos Simeonidis said the firm spok with Zafgen managmenet and there may be a 33 percent chance that the patient death... More

Leerink Partners Comments on Zafgen (ZFGN) Following Patient Death

Leerink Partners analyst Joseph Schwartz weighed in on Zafgen (NASDAQ: ZFGN) after the company announced a patient death in the ongoing Phase III bestPWS study of beloranib in Prader-Willi Syndrome (PWS).

"This news, while negative, resolves the uncertainty and speculated negativity that... More

Zafgen (ZFGN) Stock Expected to Languish Until More is Known - Cowen

Cowen analyst Phil Nadeau weighed in Zafgen (NASDAQ: ZFGN) announced that a death occurred in its ongoing double-blind, placebo controlled pivotal U.S. Phase III trial of beloranib in Prader-Willi Syndrome.

Nadeau notes the cause of the death is unknown, as was the patient's treatment assignment, thus it is unclear whether the death is drug-related.

The analyst expects the stock to languish until more is known. "Unfortunately, until... More

Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - Bloomberg

Zafgen (NASDAQ: ZFGN) has reversed and moved to the highs of the day following the announcement of a patient death.

RBC analyst said the worst case scenario has been avoided, according to Bloomberg headlines.

Shares are up 10%.

Zafgen (ZFGN) will resume trading at 12:30pm ET

Zafgen (NASDAQ: ZFGN) will resume trading at 12:30pm EDT.

Zafgen (ZFGN) Issues Statement; FDA Initiates Discussion Following Phase 3 bestPWS Death

Zafgen (NASDAQ: ZFGN) issued the following statement:

"Zafgen recently learned of a patient death which occurred in the Companys ongoing double-blind, randomized, placebo-controlled Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome, a rare genetic disorder with a high rate of mortality linked... More

Zafgen (ZFGN) Halted, News Pending

Zafgen (NASDAQ: ZFGN) Halted, News Pending